Intraoperative anaphylaxis due to aprotinin after local application of fibrin sealant diagnosed by skin tests and basophil activation tests: a case report.

Anaphylaxis Aprotinin Basophil activation test Fibrin sealant Skin test

Journal

JA clinical reports
ISSN: 2363-9024
Titre abrégé: JA Clin Rep
Pays: Germany
ID NLM: 101682121

Informations de publication

Date de publication:
08 Sep 2021
Historique:
received: 21 07 2021
accepted: 01 09 2021
revised: 25 08 2021
entrez: 8 9 2021
pubmed: 9 9 2021
medline: 9 9 2021
Statut: epublish

Résumé

There are few cases of anaphylaxis after local application of fibrin sealant diagnosed by skin tests. A 49-year-old woman underwent partial lung resection under general anesthesia. Anesthesia was induced uneventfully. Shortly after applying absorbable suture reinforcement felt that contained fibrin sealant, her systolic blood pressure fell to approximately 70 mmHg, along with facial flushing. Anaphylaxis was diagnosed based on the clinical symptoms and high serum tryptase levels. Three months after the event, skin tests were performed with all agents and were positive only for fibrin sealant vial no. 2, whose main component is aprotinin. Subsequently, basophil activation tests using fibrin sealant vial no. 2 and pure aprotinin demonstrated that the causative agent was likely aprotinin. We diagnosed aprotinin-induced anaphylaxis using skin tests and basophil activation tests. The occurrence of anaphylaxis should be considered when changes in vital signs are observed after the use of fibrin sealant.

Sections du résumé

BACKGROUND BACKGROUND
There are few cases of anaphylaxis after local application of fibrin sealant diagnosed by skin tests.
CASE PRESENTATION METHODS
A 49-year-old woman underwent partial lung resection under general anesthesia. Anesthesia was induced uneventfully. Shortly after applying absorbable suture reinforcement felt that contained fibrin sealant, her systolic blood pressure fell to approximately 70 mmHg, along with facial flushing. Anaphylaxis was diagnosed based on the clinical symptoms and high serum tryptase levels. Three months after the event, skin tests were performed with all agents and were positive only for fibrin sealant vial no. 2, whose main component is aprotinin. Subsequently, basophil activation tests using fibrin sealant vial no. 2 and pure aprotinin demonstrated that the causative agent was likely aprotinin.
CONCLUSIONS CONCLUSIONS
We diagnosed aprotinin-induced anaphylaxis using skin tests and basophil activation tests. The occurrence of anaphylaxis should be considered when changes in vital signs are observed after the use of fibrin sealant.

Identifiants

pubmed: 34495416
doi: 10.1186/s40981-021-00472-6
pii: 10.1186/s40981-021-00472-6
pmc: PMC8426421
doi:

Types de publication

Journal Article

Langues

eng

Pagination

68

Subventions

Organisme : japan society for the promotion of science
ID : 17K16721
Organisme : japan society for the promotion of science
ID : 18K08809

Informations de copyright

© 2021. The Author(s).

Références

Acta Clin Belg. 2016 Feb;71(1):19-25
pubmed: 27075810
Br J Anaesth. 2019 Jul;123(1):e38-e49
pubmed: 30916022
Plast Reconstr Surg Glob Open. 2021 Jan 22;9(1):e3382
pubmed: 33552820
Anesth Analg. 2018 May;126(5):1509-1516
pubmed: 29517573
Int J Immunopathol Pharmacol. 2011 Jul-Sep;24(3 Suppl):S61-8
pubmed: 22014927
Anaesthesia. 2005 Mar;60(3):251-6
pubmed: 15710010
Cardiovasc Surg. 2003 Aug;11 Suppl 1:17-21
pubmed: 12869984
Ann Thorac Surg. 2005 Feb;79(2):741-8
pubmed: 15680884
Allergy. 2015 Nov;70(11):1393-405
pubmed: 26198455
Anesthesiology. 2003 Sep;99(3):762-3
pubmed: 12960574
Anesth Analg. 2008 Aug;107(2):406-9
pubmed: 18633016
Ann Thorac Surg. 2007 Oct;84(4):1144-50
pubmed: 17888960
Br J Anaesth. 2019 Jul;123(1):e29-e37
pubmed: 31029409
Br J Anaesth. 2019 Jul;123(1):e50-e64
pubmed: 31130272
Anesthesiology. 1994 Oct;81(4):1074-7
pubmed: 7943819
Intern Med. 2005 Oct;44(10):1088-9
pubmed: 16293923
J Investig Allergol Clin Immunol. 2011;21(6):442-53
pubmed: 21995177
Allergy. 2014 Oct;69(10):1324-32
pubmed: 24961660
Anesthesiology. 2009 Nov;111(5):1141-50
pubmed: 19858877
Br J Anaesth. 2019 Jul;123(1):e117-e125
pubmed: 30915999

Auteurs

Masaki Orihara (M)

Department of Anesthesiology, Gunma University Graduate School of Medicine, 3-39-22, Showa-machi, Maebashi, 371-8511, Japan. orihara@gunma-u.ac.jp.

Tomonori Takazawa (T)

Intensive Care Unit, Gunma University Hospital, 3-39-15, Showa-machi, Maebashi, 371-8511, Japan.

Tatsuo Horiuchi (T)

Department of Anesthesiology, Gunma University Graduate School of Medicine, 3-39-22, Showa-machi, Maebashi, 371-8511, Japan.

Shinya Sakamoto (S)

Department of Anesthesiology, Gunma University Graduate School of Medicine, 3-39-22, Showa-machi, Maebashi, 371-8511, Japan.

Mutsumi Uchiyama (M)

Department of Anesthesiology, Saitama Cancer Center, 780 Komuro, Ina-machi, Kitaadachi, 362-0806, Japan.

Shigeru Saito (S)

Department of Anesthesiology, Gunma University Graduate School of Medicine, 3-39-22, Showa-machi, Maebashi, 371-8511, Japan.

Classifications MeSH